Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Record History

1. Minor Jul 10, 2022 Primary completion date: Jul 2022 to Sep 2022 Completion date: Jul 2035 to Sep 2035 · Eligibility criteria expanded, about 40 words · Secondary endpoints revised (2) · 1 morev8 Show 4 more changesShow less

   • Completion date: Jul 2035 to Sep 2035
   • Eligibility criteria expanded, about 40 words
   • Secondary endpoints revised (2)
   • Primary endpoints revised (2)

   See this version in full on ClinicalTrials.gov ↗

2. Notable Oct 1, 2020 Primary completion date: Mar 2020 to Jul 2022 Primary endpoints revised (2) · Trial status: Recruiting to Active, Not Recruiting · Completion date: Mar 2035 to Jul 2035 · 4 morev7 Show 7 more changesShow less

   • Primary endpoints revised (2)
   • Trial status: Recruiting to Active, Not Recruiting
   • Completion date: Mar 2035 to Jul 2035
   • Eligibility criteria expanded, about 123 words
   • Secondary endpoints: 1 to 2
   • Study description revised
   • Site details revised at 3 of 3 sites

   See this version in full on ClinicalTrials.gov ↗

3. Minor Oct 24, 2019 Completion date: Mar 2033 to Mar 2035v6
4. Minor Oct 4, 2019 4 versions Re-verified since Aug 24, 2018, no change to tracked fieldsv2-v5
5. Minor Mar 2, 2018 Study First Submitted

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.